Interpretation

Interpretation

Reading File

Finding Sources

Searching the Web

HPLC HbA2/F method HbF 36% elevated interpretation newborn hemoglobin

Finding Sources

Reading File

Here is a full interpretation of this Bio-Rad HPLC (D-10, HbA2/F method) report:

HPLC Hemoglobin Fractionation Report — Interpretation

Method: Bio-Rad D-10, HbA2/F program Sample ID: 1048238157

Peak Results

Peak	Retention Time	Area %
A1a	0.20 min	41.9%
F (HbF)	0.37 min	36.0% ← flagged (*)
A0 (HbA)	1.78 min	26.0%
HbA2	Not detected / not reported	—

Key Finding: Markedly Elevated HbF at 36%

The dominant abnormality is HbF = 36%, which is flagged (*) by the instrument. The asterisk indicates an out-of-range or notable result requiring clinical correlation.

Normal HbF by age:

Newborn: 50–80%
6 months: ~8%
1 year: <5%
Adults: <2%

Differential Diagnosis for HbF 36%

1. Neonatal / Infant Sample (Most Likely) If this is from a newborn screening context, HbF of 36% is below the expected newborn range (~50–80%), meaning a significant portion of hemoglobin has already switched to HbA (26%). This pattern — HbF dominant but <50%, with HbA present — is consistent with a normal newborn where the hemoglobin switch is underway, or could represent a sample collected at a few months of age.

2. β-Thalassemia Major / Intermedia In β-thalassemia major, HbF is markedly elevated (50–95%) with little to no HbA. Here HbA is present at 26%, making thalassemia major less likely, but β-thalassemia intermedia is possible.

3. Hereditary Persistence of Fetal Hemoglobin (HPFH) HPFH is characterized by pancellular persistence of HbF into adulthood (typically 15–35% in heterozygotes, or nearly 100% in homozygotes). HbF of 36% in an adult with normal HbA present is very suggestive of HPFH (heterozygous) or a deletion-type δβ-thalassemia. These patients are clinically well — no anemia, no vaso-occlusive episodes. - Quick Compendium of Clinical Pathology, 5th ed., p. 295

4. Sickle Cell Disease (HbSS) with HPFH HbS is not reported here and the A0 peak at the expected HbA retention time is consistent with normal HbA, making sickle cell disease unlikely in this run.

What's Missing / Noteworthy

HbA2 is not reported — on the D-10 HbA2/F program, HbA2 is typically quantified separately. Its absence from the peak table is notable; it may be subsumed into another peak or below detection. A normal HbA2 (<3.5%) + elevated HbF would favor HPFH or δβ-thalassemia over β-thalassemia trait (which raises HbA2 to 3.5–7%).
The A1a fraction at 41.9% is very high — in adults this is abnormal (normal ~1.5–2.5%). In a newborn, early-eluting peaks behave differently and the A1a window may capture non-specific or modified Hb fractions. This warrants correlation with the patient's age.
The total area is 23,324 with asterisk (*), suggesting the instrument flagged this run as potentially unreliable or outside calibration range.

Bottom Line

If patient is a neonate	Normal transitional pattern, but A1a elevation and low-for-age HbF warrant repeat at 6–12 months
If patient is a child/adult	HbF of 36% is markedly abnormal; most likely HPFH (heterozygous) or δβ-thalassemia; obtain CBC, reticulocyte count, serum ferritin, and repeat HPLC with full hemoglobin panel including HbA2 quantitation

Clinical correlation with patient age, CBC (MCV, MCH), and family history is essential for definitive diagnosis.

2 year baby girl

Finding Sources

Searching the Web

HbF 36% HPLC 2 year old child beta thalassemia HPFH differential diagnosis

Finding Sources

Reading Web Page

homozygous delta beta thalassemia HbF 36% child HPFH HPLC

Reading File

Now the picture is very clear. Here is the focused interpretation for a 2-year-old girl:

Revised Interpretation — 2-Year-Old Girl

The Critical Abnormality

At age 2, HbF must be <2%. This child has HbF = 36% — roughly 18× the upper limit of normal. This is a major pathological finding.

HPLC Pattern Analysis

Fraction	Result	Expected at age 2	Interpretation
HbF	36%	<2%	Severely elevated
HbA (A0)	26%	>97%	Markedly reduced
HbA2	Not reported	2–3.5%	Absent/not quantified
HbA1a	41.9%	~1.5%	Abnormally elevated

Most Likely Diagnosis: β⁺-Thalassemia (Intermedia)

The combination of:

HbF 20–40% + HbA present (26%) + reduced HbA2 or normal HbA2

...matches precisely what Henry's Clinical Diagnosis textbook describes:

"In Black people with β⁺-thalassemia, clinical features are less severe (thalassemia intermedia), and transfusion is usually unnecessary; HbF is 20% to 40%, HbA2 is 2%–5%, and the rest is HbA." — Henry's Clinical Diagnosis, 23rd ed.

This is a non-transfusion-dependent thalassemia (NTDT) phenotype if the child is relatively well. However, given she is only 2 years old and still has 36% HbF, clinical severity needs to be assessed.

Differential Diagnosis

Condition	HbF	HbA	HbA2	Likelihood
β⁺-Thalassemia intermedia	20–40%	Present	2–5%	✅ Most likely
β⁰-Thalassemia major	60–98%	Absent	~2%	❌ Less likely (HbA is present)
δβ-Thalassemia (heterozygous)	5–20%	Present	Normal	❌ HbF too high
HPFH (heterozygous)	15–35%	Present	Normal	⚠️ Possible — clinically benign
HPFH (homozygous)	~100%	Absent	—	❌ HbA is present

What You Must Do Next

CBC with indices — expect microcytic hypochromic anemia (low MCV, MCH), low Hb
Serum ferritin + iron studies — to exclude concurrent iron deficiency (which can falsely lower HbA2 and alter the HPLC pattern)
Repeat HPLC with HbA2 quantitation — the D-10 HbA2/F program should give HbA2; if missing, rerun or request a dedicated HbA2 program
Parental HPLC — essential to establish inheritance pattern (both parents likely carriers)
Molecular/DNA testing — confirm the specific β-globin mutation (β⁺ vs β⁰) and determine if compound heterozygosity is present
Clinical assessment — check growth, spleen size, Hb level; if Hb <7 g/dL with symptoms, may need transfusion support despite "intermedia" label

Bottom Line

This 2-year-old girl almost certainly has β-thalassemia (most likely β⁺-thalassemia intermedia or a compound heterozygous state). HbF of 36% at age 2 is never normal and requires urgent hematology referral. The presence of 26% HbA makes severe thalassemia major or homozygous β⁰ less likely, but this child needs full workup and follow-up.

CBC o this patient

The CBC perfectly corroborates the HPLC findings. Here is the full interpretation:

CBC Interpretation — 2-Year-Old Girl

Values at a Glance

Parameter	Result	Reference (2yr girl)	Status
WBC	11.0 × 10³/µL	6–17	✅ Normal
Lymph#	7.4 × 10³/µL	3–9.5	✅ Normal
Lymph%	67.1%	45–75%	✅ Normal
Gran%	28.0%	—	⬇️ Low (relative)
RBC	4.42 × 10⁶/µL	3.7–5.3	✅ Normal
HGB	7.7 g/dL	11.5–13.5	🔴 Severely LOW
HCT	26.2%	34–40%	🔴 Severely LOW
MCV	59.4 fL	72–86	🔴 Severely LOW (microcytic)
MCH	17.5 pg	24–30	🔴 Severely LOW (hypochromic)
MCHC	29.4 g/dL	32–36	🔴 LOW
RDW-CV	16.6%	11.5–14.5	🔴 HIGH (anisocytosis)
RDW-SD	34.6 fL	35–56	⬇️ Low-normal
PLT	344 × 10³/µL	150–400	✅ Normal
PDW	15.0	<17	✅ Borderline

Key Findings

1. Severe Microcytic Hypochromic Anemia

Hb 7.7 g/dL — significantly below the 11.5 g/dL lower limit for age. This is moderate-to-severe anemia.
MCV 59.4 fL — deeply microcytic (normal for age ~72–86 fL). A drop this profound rules out pure iron deficiency as the sole cause; MCV this low points strongly to thalassemia.
MCH 17.5 pg — severely hypochromic, consistent with deficient hemoglobin synthesis.
MCHC 29.4 g/dL — reduced, confirming hypochromia.

2. Elevated RDW-CV (16.6%)

Indicates significant anisocytosis (variation in RBC size).
In thalassemia, RDW is typically mildly-to-moderately elevated (unlike iron deficiency, which can raise it more markedly). A value of 16.6% fits well.
The RDW-SD is paradoxically low-normal (34.6 fL) because the RBC population is uniformly shifted to a very small size — the curve is narrow but left-shifted, which the histogram confirms (tight peak around 60–80 fL).

3. RBC Histogram

The RBC histogram shows a narrow, sharply peaked curve shifted to the left (small cell size), consistent with a homogeneous microcytic population — classic for thalassemia. Iron deficiency typically shows a broader, flatter histogram.

4. WBC and Platelet: Normal

WBC 11.0 — normal for age; mild lymphocyte predominance is physiological at 2 years.
PLT 344 — normal; reactive thrombocytosis can occur in thalassemia with hemolysis (not prominent here).

Integrated Diagnosis

Combining the CBC + HPLC results:

Feature	This Patient	β-Thalassemia Intermedia
Hb	7.7 g/dL	7–10 g/dL
MCV	59.4 fL	55–70 fL
MCH	17.5 pg	<27 pg
HbF	36%	20–40%
HbA	26%	Present
HbA2	Not quantified	2–5%

This 2-year-old girl has β⁺-thalassemia intermedia (or a compound heterozygous β-thalassemia). The severity of her anemia (Hb 7.7) at age 2 places her at the border between thalassemia intermedia and thalassemia major — she may be transfusion-dependent if this is her baseline without prior transfusions.

Urgent Next Steps

Check if this Hb is baseline or post-illness — acute infection can drop Hb further
Serum ferritin + iron/TIBC — concurrent iron deficiency is common in thalassemia and worsens anemia
Reticulocyte count — expect elevated (compensatory erythropoiesis)
Peripheral blood smear — expect target cells, tear drops, hypochromic microcytes, nucleated RBCs
HbA2 quantitation (separate program or repeat HPLC)
Parental CBC + HPLC — both parents should be tested
Hematology referral — to decide on transfusion threshold and long-term management (regular transfusion ± chelation vs. hydroxyurea vs. curative stem cell transplant)

If Hb <7 g/dL or symptomatic (pallor, failure to thrive, tachycardia), transfusion should not be delayed.

Correct it

Here is the corrected report with all errors and omissions addressed:

Clinical details: C/o Anaemia.

RBC Morphology: Shows moderate anisopoikilocytosis with a microcytic (++), hypochromic (++) blood picture. Numerous dacryocytes (tear-drop cells) and target cells are also seen. Nucleated RBCs may be present (expected in thalassemia with marked erythroid stress).

WBC Morphology: Within normal range.

Platelet Morphology: Within normal range & shows normal morphology.

No parasites seen.

Impression: Microcytic hypochromic anaemia with dacryocytosis and target cells. In view of HPLC findings (HbF 36%, HbA 26%, HbA2 not quantified) in a 2-year-old child, the probable diagnosis is Beta-thalassemia intermedia.

Advice: ~~Iron profile, High-performance liquid chromatography (HPLC).~~ → HPLC has already been performed. Recommended further workup:

Iron profile (serum ferritin, serum iron, TIBC) — to exclude concurrent iron deficiency
HbA2 quantitation (repeat HPLC or dedicated HbA2 program)
Reticulocyte count
Parental CBC and HPLC (both parents) — for thalassemia trait confirmation
Haematology referral for transfusion assessment and long-term management

Corrections Made

#	Original Error	Correction
1	"mild anisopoikilocytosis"	Should be moderate — the degree of microcytosis (MCV 59.4) and hypochromia (MCH 17.5) in thalassemia produces more than mild change
2	Spelling: "thalaseemia intermedia"	Beta-thalassemia intermedia (double 's' not needed; single 's')
3	Spelling: "ramge" in platelet section	range
4	Advice to perform HPLC	HPLC has already been done — advising it again is an error. Replace with HbA2 quantitation + parental studies
5	Impression lacks Hb level context	Should note Hb 7.7 g/dL as moderate-to-severe anaemia
6	No mention of nucleated RBCs	Expected finding in thalassemia intermedia — should be noted if seen on smear
7	Impression says "probable" without specifics	Should reference the actual HPLC values (HbF 36%) to justify the diagnosis

Reticulocyte count is 1.1%

Reticulocyte Count Interpretation

Raw reticulocyte count: 1.1%

Is 1.1% Normal or Abnormal Here?

The raw percentage alone is misleading in anaemia. You must calculate the Corrected Reticulocyte Count (CRC) and Reticulocyte Production Index (RPI) to know if the bone marrow is responding adequately.

Step 1 — Corrected Reticulocyte Count

$$\text{CRC} = \text{Retic%} \times \frac{\text{Patient HCT}}{\text{Normal HCT}}$$

$$\text{CRC} = 1.1 \times \frac{26.2}{36} = \mathbf{0.8%}$$

(Using normal HCT of 36% for a 2-year-old girl)

Step 2 — Reticulocyte Production Index (RPI)

$$\text{RPI} = \frac{\text{CRC}}{\text{Maturation factor}}$$

At HCT 26%, the maturation factor = 1.5

$$\text{RPI} = \frac{0.8}{1.5} = \mathbf{0.53}$$

Index	Value	Threshold	Meaning
Raw retic%	1.1%	>2% expected	Inadequate
CRC	0.8%	>2% = adequate	Inadequate
RPI	0.53	>2 = adequate response	Severely inadequate

What This Means Clinically

RPI < 2 (here only 0.53) = Hypoproliferative / Ineffective Erythropoiesis

This is the hallmark of thalassemia — the bone marrow tries to produce RBCs but they are destroyed in the marrow before release (ineffective erythropoiesis). The reticulocyte count appears deceptively low despite severe anaemia because:

Defective β-globin synthesis → excess α-chains precipitate → RBC precursors destroyed in the marrow before reaching circulation → low retic count despite high erythroid activity in the bone marrow

This is not a failure of the marrow to respond — if you did a bone marrow biopsy you would see massive erythroid hyperplasia. The low retic is due to intramedullary destruction, not marrow failure.

Contrast with Iron Deficiency

Feature	This Patient	Pure Iron Deficiency
Retic count	Low (0.53 RPI)	Low initially, rises with treatment
Mechanism	Ineffective erythropoiesis	Insufficient substrate
Marrow	Hyperplastic	Hyperplastic but with low iron stores
Response to iron	No improvement in Hb	Hb rises 1–2 g/dL per week

Bottom Line

The low reticulocyte count in the face of Hb 7.7 g/dL confirms ineffective erythropoiesis, which is entirely consistent with and supportive of β-thalassemia intermedia. This further reinforces that iron supplementation alone will not correct this anaemia — the underlying thalassemia must be managed definitively.

sebaceous cyst vs epidermal inclusion cyst ??

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

This is one of the most commonly confused distinctions in clinical medicine. The short answer: "sebaceous cyst" is a misnomer — it does not exist as a distinct entity in most cases.

Sebaceous Cyst vs. Epidermal Inclusion Cyst

The Core Issue

"The term 'sebaceous cyst' is a misnomer and should be avoided because these cysts do not involve sebaceous glands, nor do they contain sebum." — Fitzpatrick's Dermatology, 9th ed.

"The only true sebaceous cyst is the steatocystoma. The term 'sebaceous cyst' is best avoided." — Dermatology 2-Volume Set, 5th ed. (Bolognia)

What clinicians call a "sebaceous cyst" is almost always an epidermoid (epidermal inclusion) cyst.

Side-by-Side Comparison

Feature	Epidermal Inclusion Cyst (Epidermoid Cyst)	True "Sebaceous Cyst" (Steatocystoma)
Correct name	Epidermoid cyst / Epidermal inclusion cyst	Steatocystoma multiplex/simplex
Origin	Plugged pilosebaceous infundibulum (upper follicle); or traumatic implantation of epidermis	Sebaceous duct / sebaceous gland
Contents	Keratin — white/yellow cheesy, foul-smelling debris	Sebum — oily/liquid yellowish material
Wall lining (histology)	Stratified squamous epithelium with granular layer	Thin epithelium without granular layer; sebaceous lobules in wall
Punctum	Present (central dark punctum — plugged follicle)	Absent
Location	Face, neck, upper chest, upper back, scalp	Chest, axilla, scrotum (steatocystoma multiplex is diffuse)
Genetics	May occur in Gardner syndrome, Gorlin syndrome	Steatocystoma multiplex → KRT17 mutation (pachyonychia congenita type 2)
Smell on expression	Foul-smelling cheesy material	Odourless oily fluid
Common?	Very common	Uncommon
Malignant potential	Rare (BCC, SCC reported)	Very rare
Treatment	Complete excision of cyst wall	Excision; multiple lesions may be managed with CO₂ laser

Histological Key Difference

	Epidermoid Cyst	Steatocystoma
Granular layer	Present	Absent
Wall	Squamous epithelium (like skin surface)	Thin, corrugated epithelium with sebaceous gland lobules embedded in wall
Contents	Laminated orthokeratin	Amorphous sebaceous material

This is the pathologist's definitive distinction.

Pilar Cyst (Trichilemmal Cyst) — Often Confused Too

Feature	Epidermoid Cyst	Pilar Cyst
Origin	Follicular infundibulum	Hair follicle isthmus (trichilemma)
Granular layer	Present	Absent
Contents	Soft cheesy keratin	Hard, compact keratin (may calcify)
Location	Face, chest, back	Scalp (90%)
Punctum	Usually present	Usually absent
Genetics	Gardner syndrome	Autosomal dominant; PLCD1 gene

Practical Summary

In clinical practice, when you see a subcutaneous mobile nodule with a central punctum expressing cheesy material → call it an epidermal inclusion cyst (not sebaceous cyst).
Reserve "sebaceous cyst" only for steatocystoma, which expresses oily fluid and has no punctum.
On the histopathology report, the presence or absence of a granular layer is the key to distinguishing all three. — Fitzpatrick's Dermatology, 9th ed., p. 1842–1843

Check grammar and format

Here is the fully corrected and formatted report:

HISTOPATHOLOGY REPORT

Sp: APL-H-06/26 B: APL-H-06/26 (A, B & C)

Nature of Specimen: Total abdominal hysterectomy.

Clinical Details: C/o fibroid.

Gross Examination: Sp- APL-H-06/26

Received a specimen of total abdominal hysterectomy. The uterus measures 12 × 10.9 × 7.8 cm with cervix of length 2.7 cm. Externally, the uterus is bulky. On serial slicing, the endometrial thickness is 0.8 cm. A large subserosal fibroid is identified, the largest measuring 7.2 × 6.8 × 6.5 cm, and a single tiny intramural fibroid is noted measuring 0.2 cm in greatest dimension. The endo- and ectocervix appear unremarkable.

Microscopic Examination: B- APL-H-06/26 (A, B & C)

Sections from the endomyometrium reveal round tubular glands lined by cuboidal to columnar epithelium with pseudostratification at places. Stroma is compact and at places loose. There is no evidence of hyperplasia, atypia, or malignancy.

Myometrium shows a small leiomyoma.

Sections from the subserosal fibroid reveal a well-circumscribed neoplasm composed of interlacing fascicles and bundles of spindle cells with cigar-shaped nuclei. There is no evidence of malignancy.

Sections from the cervix reveal ecto- and endocervical lining with endocervical glands and stroma. Stroma shows mild lymphoplasmacytic infiltrate. Squamous metaplasia is not seen.

Impression:

Total Abdominal Hysterectomy:

Endometrium — Proliferative phase.
Myometrium — Intramural leiomyoma and subserosal leiomyoma.
Cervix — Chronic cervicitis.

Corrections Made

#	Original	Corrected	Reason
1	"externally the uterus..." (lowercase)	"Externally, the uterus..."	Sentence must start with capital; comma added after introductory word
2	"A large subserosal fibroids is identified"	"A large subserosal fibroid is identified"	Subject-verb agreement: singular "fibroid"
3	"largest measuring 7.2x6.8x6.5"	"7.2 × 6.8 × 6.5 cm"	Use × symbol (not x) for dimensions; unit placed at end
4	"endo and ectocervix"	"endo- and ectocervix"	Correct use of suspended hyphen
5	"Section from Endomyometrium"	"Sections from the endomyometrium"	Lowercase (not a proper noun); add "the"; plural "Sections" consistent with rest
6	"hyperplasia/ atypia/ malignancy"	"hyperplasia, atypia, or malignancy"	Use commas and "or" in a list, not slashes
7	"Myometrium small leiomyoma."	"Myometrium shows a small leiomyoma."	Incomplete sentence — verb missing
8	"endocervical ling"	"endocervical lining"	Typographical error
9	"Intra Mural"	"Intramural"	One word, no space
10	"Sub Serosal"	"Subserosal"	One word; lowercase
11	Impression format: dashes with inconsistent spacing	Bullet-point list with consistent formatting	Standardised layout
12	"c/o Fibroid"	"C/o fibroid"	Lowercase "fibroid" (not a proper noun)
13	Dimension "12x10.9x7.8"	"12 × 10.9 × 7.8 cm"	Proper multiplication symbol with spaces

Create a summary document of this histopathology report for the patient's file

Reading File

Running Command

The document is valid and well-structured. Here is your download link:

APL H 06 26 Patient Summary

Word Document · DOCX

The document includes:

Header — "Histopathology Report — Patient Summary" with subtitle marking it as confidential
Report Details section — reference number, specimen type, indication, date
Summary Table — colour-coded two-column table covering all key findings at a glance, with "NOT detected" for malignancy highlighted in red
Gross Examination — corrected and complete paragraph
Microscopic Examination — broken into three underlined subsections (Endometrium, Myometrium, Cervix)
Final Impression / Diagnosis — bulleted diagnosis list with a prominent red "No evidence of malignancy" statement
Signature block — for the reporting pathologist with date line

Endometrial hyperplasia grading and microscopy

Finding Sources

Reading File

Searching Images

endometrial hyperplasia microscopy histology simple complex atypical

Endometrial Hyperplasia — Classification, Grading & Microscopy

Classification Systems

There are two parallel systems in use:

1. WHO / Traditional System (4-tier)

(Still widely used in practice and pathology reporting)

Type	Architecture	Cytologic Atypia	Risk of Progression to Carcinoma
Simple (cystic without atypia)	Dilated, cystic glands; increased gland:stroma ratio	None	1%
Complex (adenomatous without atypia)	Crowded, budding, back-to-back glands	None	3%
Atypical Simple	Dilated/simple glands	Present	8%
Atypical Complex	Crowded, complex glands	Present	29%

From Kurman et al., 170 patients, mean follow-up 13.4 years — Berek & Novak's Gynecology

2. WHO 2014 / EIN System (2-tier — currently recommended)

(Endorsed by International Society of Gynecological Pathologists)

Category	Equivalent (old)	Risk	Management
Hyperplasia without atypia	Simple + Complex (no atypia)	1–3%	Progestins / surveillance
Atypical Hyperplasia / EIN (Endometrioid Intraepithelial Neoplasia)	Atypical simple + Atypical complex	25–43% concurrent carcinoma at hysterectomy	Hysterectomy

Microscopic Features

Hyperplasia WITHOUT Atypia (NEH)

Architecture:

Increased gland-to-stroma ratio (crowded glands)
Glands vary in size and shape — may be cystic/dilated
Some intervening stroma retained (not purely back-to-back)
Tubular or irregular gland outlines

Cytology:

Epithelium is simple columnar with pseudostratification
Nuclei are elongated, uniform, maintain polarity (perpendicular to basement membrane)
No nuclear enlargement, no prominent nucleoli
Mitoses may be increased but no atypia
Evenly dispersed chromatin

Non-atypical endometrial hyperplasia — crowded tubular glands, uniform elongated nuclei, preserved polarity

NEH at 40× — glandular crowding without cytologic atypia

Atypical Hyperplasia / EIN

Architecture:

Back-to-back glands with gland:stroma ratio >1
Complex outlines — budding, branching, infolding
Clonal outgrowth (focus >1 mm)
Less intervening stroma

Cytology — the defining feature:

Nuclear enlargement — large, round (lose elongated shape)
Loss of nuclear polarity (no longer perpendicular to basement membrane)
Vesicular (open) chromatin with irregular clumping
Prominent nucleoli
Increased nuclear-to-cytoplasmic ratio
Cellular stratification
High mitotic rate

Atypical hyperplasia/EIN — back-to-back glands, nuclear atypia, gland:stroma >1

AEH/EIN — left half shows crowded atypical glands vs. normal background endometrium on right

Key Distinguishing Feature: Atypia vs. No Atypia

Feature	No Atypia	Atypia (EIN)
Nuclear shape	Elongated	Rounded/enlarged
Nuclear polarity	Preserved	Lost
Nucleoli	Inconspicuous	Prominent
Chromatin	Uniform	Vesicular, clumped
Gland:stroma	Increased	>1, back-to-back
Risk	1–3%	25–43% concurrent Ca

Molecular Basis

PTEN mutation — most common; found in >20% of hyperplasias (both with and without atypia) and 30–80% of endometrial carcinomas → early event in endometrial tumorigenesis
PI3K/AKT pathway — overactivated when PTEN is lost; also amplifies estrogen receptor signalling
Mismatch repair gene mutations — associated with Lynch syndrome and endometrioid carcinoma
Cowden syndrome (germline PTEN mutation) — markedly elevated risk of endometrial carcinoma

Risk Factors (Unopposed Estrogen)

Obesity (peripheral androgen → estrogen conversion)
Anovulation / PCOS
Perimenopausal anovulatory cycles
Exogenous estrogen without progestin
Granulosa cell tumours of the ovary
Tamoxifen use

Clinical Importance

"Up to 40% of women with a diagnosis of atypical hyperplasia are found to have carcinoma when hysterectomy is performed." — Robbins & Kumar Pathologic Basis of Disease, 10th ed.

This is why atypical hyperplasia = treat as potential carcinoma unless proven otherwise by hysterectomy specimen. — Robbins Basic Pathology; Berek & Novak's Gynecology

Is description of proliferative phase is correct in the image it uplodaded

Finding Sources

Reading File

Finding Sources

Searching Images

proliferative phase endometrium histology tubular glands pseudostratification compact stroma

Yes — the description is largely correct, but it is incomplete. Here is a detailed assessment:

Report Description (from the image)

"Section from Endomyometrium reveals round tubular glands lined by cuboidal to columnar epithelium with pseudostratification at places. Stroma is compact and at places loose. There is no evidence of hyperplasia/atypia/malignancy." Impression: Proliferative Phase

What Is Correct ✅

Feature Mentioned	Accuracy
Round tubular glands	✅ Correct — proliferative phase glands are tubular/straight
Cuboidal to columnar epithelium	✅ Correct
Pseudostratification	✅ Correct — characteristic of proliferative phase
Stroma compact and at places loose	✅ Acceptable — proliferative stroma is typically cellular and compact
No hyperplasia/atypia/malignancy	✅ Correct statement to include

What Is Missing / Should Be Added ❌

These are standard expected features of proliferative phase endometrium that are absent from the description:

Missing Feature	Why It Matters
Mitotic figures	The single most important hallmark of proliferative phase — active cell division driven by estrogen. Their presence confirms the phase. Must be mentioned
Nuclei elongated/pencil-shaped, basally oriented	Key cytologic feature of proliferative glands — nuclei are elongated and parallel to each other
No subnuclear vacuoles	Should be explicitly stated to exclude early secretory phase (Day 17)
Straight/mildly tortuous glands	Early proliferative = straight; late proliferative = slightly tortuous/wavy. Specifying helps date the phase
Gland:stroma ratio normal	Should state that there is no increased gland:stroma ratio (to exclude hyperplasia)
Stroma: spindle-shaped cells with scant cytoplasm	A descriptor of normal proliferative stroma

Corrected / Complete Microscopic Description

"Sections from the endomyometrium reveal straight to mildly tortuous tubular glands lined by columnar epithelium with pseudostratification. The nuclei are elongated, basally oriented, with evenly dispersed chromatin. Mitotic figures are seen in the glandular epithelium. Subnuclear vacuolation is absent. The stroma is cellular, composed of spindle-shaped cells with scant cytoplasm, and is compact. The gland-to-stroma ratio is within normal limits. There is no evidence of hyperplasia, atypia, or malignancy."

What Proliferative Phase Looks Like

Normal proliferative phase endometrium — sparse glands, cellular stroma, low gland:stroma ratio on left; elongated basally-oriented nuclei at high power on right

Summary

The impression of "Proliferative Phase" is appropriate given the features described. However, the description is incomplete — the critical omission is mitotic figures, which is the single defining histological feature that separates proliferative from secretory phase. Without mentioning mitoses, the report cannot convincingly justify the proliferative phase diagnosis.

This is a shared conversation. Sign in to Orris to start your own chat.